bendamustine hydrochloride has been researched along with navitoclax in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ackler, S; Boghaert, ER; Chen, J; Clarin, J; Foster, K; Jin, S; Leverson, JD; Mitten, MJ; Phillips, DC; Schlessinger, S; Wang, B | 1 |
1 other study(ies) available for bendamustine hydrochloride and navitoclax
| Article | Year |
|---|---|
Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
Topics: Aniline Compounds; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Line, Tumor; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Nitrogen Mustard Compounds; Proto-Oncogene Proteins c-bcl-2; Rituximab; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |